Download PDF
Thromb Haemost 1984; 51(01): 037-041
DOI: 10.1055/s-0038-1661014
Original Article
Schattauer GmbH Stuttgart

The Effect of Collagen Mediated Platelet Release on Plasma Prekallikrein Activation

K M Weerasinghe
The Thrombosis Research Unit, King’s College Hospital Medical School, London, U.K.
,
M F Scully
The Thrombosis Research Unit, King’s College Hospital Medical School, London, U.K.
,
V V Kakkar
The Thrombosis Research Unit, King’s College Hospital Medical School, London, U.K.
› Author Affiliations
Further Information

Publication History

Received 22 June 1983

Accepted 09 November 1983

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Collagen mediated platelet aggregation caused -5.6 ± 6.7% inhibition and +39.1 ± 15.2% potentiation of prekallikrein activation in plasma from normal healthy volunteers between 20–40 and 50–65 years of age, respectively (n = 15, p <0.01). The amouns of platelet factor-four (PF4) released in the two groups were not significantly different. Collagen treatment in the presence of indomethacin caused +11.5 ± 3.6% and +59.6 ± 19.5% potentiation in the 20–40 and 50–65 age groups respectively (p <0.02). Adrenaline mediated platelet aggregation caused -55.2 ± 7.1% and -35.2 ± 8.3% inhibition in the 20–40 and 50–65 age groups, respectively. Collagen treatment of platelet-deficient-plasma and platelet-rich-plasma in EDTA also caused potentiation of prekallikrein activation.

The results indicate that the observed degree of prekallikrein activation after platelet aggregation is a net result of the inhibitory effect of PF4 and the potentiatory effect of activated platelets. The potentiatory effect was greater after collagen treatment as compared to adrenaline treatment, and in the 50–65 age group as compared to the 20–40 age group.

Key Words

Collagen - Platelets - Prekallikrein - Platelet factor 4
 

  • References

  • 1 Cochrane CG, Griffin JH. Molecular assembly in the contact phase of the Hageman factor system. Am J Med 1979; 67: 657-664
    CrossrefPubMedGoogle Scholar
  • 2 Margolis J. The interrelationship of coagulation of plasma and release of peptides. Ann N Y Acad Sci 1969; 104: 133-145
    PubMedGoogle Scholar
  • 3 Kluft C, Trumpi-Kalshoven MM, Jie AF H. Crucial conditions for the determination of prekallikrein levels in plasma with chromogenic substrates. In: Chromogenic peptide substrates. Scully F, Kakkar VV. (Eds) Churchill Livingstone; Edinburgh: 1978. pp 84-92
    Google Scholar
  • 4 Nossel HL, Rubin H, Drillings M, Hsieh R. Inhibition of Hagemann factor activation. J Clin Invest 1968; 47: 1172-1180
    CrossrefPubMedGoogle Scholar
  • 5 Scully MF, Weerasinghe K, Kakkar VV. Inhibition of contact activation by platelet factor-4. Throm Res 1980; 20: 461-466
    CrossrefPubMedGoogle Scholar
  • 6 Deutsch E, Johnson SA, Seegers WH. Differentiation of certain platelet factors related to blood coagulation. Circ Res 1955; 3: 110-115
    CrossrefPubMedGoogle Scholar
  • 7 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282
    PubMedGoogle Scholar
  • 8 Weiss HJ, Lages BA, Witte LD, Kaplan KL, Goodman de WS, Nossel HL, Baumgartner HR. Storage pool disease: Evidence for clinical and biochemical heterogeneity. Thromb Haemostas 1977; 38: 3-8
    PubMedGoogle Scholar
  • 9 Holmsen H. Biochemistry of the platelet release reaction In: Biochemistry and pharmacology of platelets. Ciba Foundation Symposium 1975; 33: 175-205
    PubMedGoogle Scholar
  • 10 Abramson HA. The electrophoresis of the blood platelets of the horse with reference to their origin and thrombus formation. J Exp Med 1928; 47: 677-683
    CrossrefPubMedGoogle Scholar
  • 11 Hampton JR, Mitchell JR A. Effect of aggregating agents on the electrophoretic mobility of human platelets. Br Med J 1966; 1: 1074-1077
    CrossrefPubMedGoogle Scholar
  • 12 Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57: 106-118
    CrossrefPubMedGoogle Scholar
  • 13 Niewiarowski S, Baukowski E, Fiedoruk T. Adsorption of Hageman Factor (factor XII) on collagen. Experentia 1964; 20: 367-375
    CrossrefPubMedGoogle Scholar
  • 14 Cochrane CG, Revak SD, Aikin BS, Wuepper KD. The structural characteristics and activation of Hageman factor. In: Inflammation, mechanism and control. Lepow IH, Ward PA. (eds) Academic Press; New York: 1972. pp 119-138
    Google Scholar
  • 15 Ludlam CA, Moore S, Boltan AE, Pepper DS, Cash JD. The release of a human platelet specific protein as measured by radioimmuno assay. Thromb Res 1975; 6: 543-550
    CrossrefPubMedGoogle Scholar
  • 16 Claeson G, Aurell L, Karlson G, Gustavsson S, Friberger P, Avielly S, Simonsson R. Design of chromogenic peptide substrates. In: Chromogenic peptide substrates. Scully MF, Kakkar VV. (Eds) Churchill Livingstone; Edinburgh: 1978. pp 20-31
    Google Scholar
  • 17 Weerasinghe KM, Scully MF, Kakkar VV. A platelet derived inhibitor of plasma prekallikrein activation. Thromb Res (in press).
    PubMedGoogle Scholar
  • 18 Dawes J, Pumhrey CW, McLaren KM, Prowse CV, Pepper DS. TTie in vivo release of human platelet factor four by heparin. Thromb Res 1982; 27: 65-76
    CrossrefPubMedGoogle Scholar
  • 19 Farbiszewski R, Niewiarowski S, Worowski K, Lipiński B. Release of platelet factor 4 in vivo during intravascular coagulation and in thrombotic states. Thrombos Diathes Haemorrh 1968; 19: 578-583
    PubMedGoogle Scholar
  • 20 Handin RI, McDonough M, Lesch M. Elevation of platelet factor four in acute myocardial infarction Measurement by radioimmuno assay. J Lab clin Med 1978; 91: 340-349
    PubMedGoogle Scholar
  • 21 Nichols AB, Owen J, Kaplan KL, Sciacca RR, Canon PJ, Nossel HL. Fibrinopeptide A, Platelet factor4 and p-Thromboglobulin levels in coronary heart diseases. Blood 1982; 60: 650-654
    PubMedGoogle Scholar